What is the appropriate prescription for uncomplicated enteric fever (typhoid/paratyphoid) in a 55 kg male?

Prescription for Enteric Fever in a 55 kg Male

For a 55 kg male with uncomplicated enteric fever, prescribe azithromycin 500 mg orally once daily for 7 days, as this is the preferred first-line treatment with superior efficacy and lower relapse rates compared to alternatives, particularly given widespread fluoroquinolone resistance exceeding 70% in endemic regions. 1, 2

Rationale for Azithromycin as First-Line Therapy

• Azithromycin reduces clinical failure by 52% compared to fluoroquinolones (OR 0.48,95% CI 0.26-0.89) and shortens hospital stays by approximately 1 day 1, 2

• The relapse risk with azithromycin is 91% lower than with ceftriaxone (OR 0.09,95% CI 0.01-0.70), making it superior for preventing recurrence 1, 2

• More than 70% of Salmonella Typhi and S. Paratyphi isolates from South and Southeast Asia are fluoroquinolone-resistant, with some regions approaching 96% resistance 1, 3, 2

• Azithromycin maintains activity against multidrug-resistant strains (resistant to chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole) 2, 4, 5

• Recent studies demonstrate 98.1% effectiveness of azithromycin in treating extensively drug-resistant enteric fever 6

Complete Prescription Details

Medication: Azithromycin
Dose: 500 mg
Route: Oral
Frequency: Once daily
Duration: 7 days
Total quantity: 7 tablets of 500 mg 1, 2

Alternative Treatment Options (If Azithromycin Unavailable or Contraindicated)

Second-Line: Ceftriaxone

• Dose: 2 grams IV once daily for 5-7 days 7
• Ceftriaxone is appropriate for quinolone-resistant strains or when oral therapy is not tolerated 1, 7
• All isolates imported to the UK in 2006 were sensitive to ceftriaxone despite 70% fluoroquinolone resistance 1, 3
• Fever clearance occurs within 4-5 days with ceftriaxone 7

Fluoroquinolones (ONLY if susceptibility confirmed)

• Ciprofloxacin 500 mg orally every 12 hours for 10 days 8
• Fluoroquinolones should be used only when culture demonstrates nalidixic acid susceptibility and the infection is not acquired from South or Southeast Asia 3, 2
• When susceptibility is confirmed, fluoroquinolones achieve fever clearance in fewer than 4 days and cure rates exceeding 96% 1, 3
• Critical caveat: Ciprofloxacin disc testing alone is unreliable; nalidixic acid disc positivity is required to confirm true fluoroquinolone sensitivity 1, 3

Expected Clinical Response and Monitoring

• Fever typically resolves within 4-5 days of appropriate azithromycin therapy 2, 7
• If no clinical improvement by day 5, consider antimicrobial resistance or alternative diagnosis 2
• Blood cultures should be obtained before starting antibiotics whenever possible, as they have the highest diagnostic yield (40-80% sensitivity) within the first week of symptom onset 1, 3, 2

Critical Treatment Principles

• Complete the full 7-day course even if fever resolves early; premature discontinuation increases relapse risk to 10-15% 2, 7
• Do not use ciprofloxacin empirically for cases from South or Southeast Asia due to widespread resistance 3, 2
• Avoid cefixime as first-line therapy; treatment failure rates range from 4% to 37.6%, with a 13-fold higher risk of clinical failure compared to fluoroquinolones (RR 13.39,95% CI 3.24-55.39) 1, 3, 2

Adverse Effects to Monitor

• Azithromycin is generally well tolerated; most common adverse events are mild gastrointestinal symptoms including nausea, vomiting, abdominal pain, and diarrhea 2
• Monitor for QT-prolonging drug interactions when prescribing azithromycin 2

When to Escalate Care

• Complications such as gastrointestinal bleeding, intestinal perforation, and typhoid encephalopathy occur in 10-15% of patients, particularly if illness duration exceeds 2 weeks before effective treatment 1, 3, 2
• If the patient develops hemodynamic instability or signs of severe sepsis, initiate empirical IV ceftriaxone 2 grams daily immediately after obtaining blood cultures 3, 2
• Intestinal perforation requires surgical intervention; simple excision and closure achieves approximately 88% success rates 2

Geographic and Resistance Considerations

• For travelers returning from sub-Saharan Africa, fluoroquinolones may remain appropriate first-line agents provided susceptibility is confirmed 3
• For patients from Asia (South and Southeast Asia), empiric azithromycin is strongly preferred because fluoroquinolone resistance exceeds 70% in isolates from this region 1, 3, 2
• Pakistan has documented both ciprofloxacin-resistant and ceftriaxone-resistant typhoid strains; local resistance patterns should guide therapy when known 9